{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:01:09Z","timestamp":1791277269215,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.bbmt.2018.12.068","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T03:08:18Z","timestamp":1545102498000},"page":"e76-e85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6901-0782","authenticated-orcid":false,"given":"Ankit J.","family":"Kansagra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore W.","family":"Laetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E.","family":"Heslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna V.","family":"Komanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Gastineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-4889","authenticated-orcid":false,"given":"Christian","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hudecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0222-1766","authenticated-orcid":false,"given":"Leslie","family":"Andritsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-432X","authenticated-orcid":false,"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-8474","authenticated-orcid":false,"given":"Armin","family":"Ghobadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar I.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7665-7100","authenticated-orcid":false,"given":"Joshua","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2767-3830","authenticated-orcid":false,"given":"Saad","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien D.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam J.","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Z.","family":"Pavletic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2759-7604","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-7927","authenticated-orcid":false,"given":"Shahrukh K.","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.12.068_bib0001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Medicine"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0003","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-017-0239-0","article-title":"The why, what, and how of the new FACT standards for immune effector cells","volume":"5","author":"Maus","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"13 suppl","key":"10.1016\/j.bbmt.2018.12.068_bib0004","article-title":"T cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential","volume":"78","author":"Das Rajat","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0005","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41408-017-0023-x","article-title":"CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment","volume":"7","author":"Mejstrikova","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0006","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood.V126.23.681.681","article-title":"Durable remission in children with relapsed\/refractory ALL treated with T cells engineered with a CD19 - targeted chimeric antigen receptor (CTL019)","volume":"126","author":"Grupp","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0007","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0008","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0009","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0010","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0011","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0012","doi-asserted-by":"crossref","first-page":"e61338","DOI":"10.1371\/journal.pone.0061338","article-title":"CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia","volume":"8","author":"Davila","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0013","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0014","first-page":"2018","article-title":"Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophoshamide preparative regimen and post-CAR hematopoietic stem cell transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0015","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0016","series-title":"BMT Tandem Scientific Meeting","article-title":"Chimeric antigen receptor T-cell therapy can render patients with ALL into PCR-negative remission and can be an effective bridge to transplant","author":"Shalabi","year":"2018"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0017","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","author":"Grupp","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0018","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbmt.2018.12.068_bib0019","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1027469","article-title":"Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia","volume":"4","author":"Dai","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0020","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0021","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0022","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2017-08-752121","article-title":"Posttransplant chimeric antigen receptor therapy","volume":"131","author":"Smith","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0023","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0142","article-title":"ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells","author":"Lee","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0025","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0026","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0027","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0028","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2018.02.012","article-title":"Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts","author":"Zheng","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0030","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade is a predictive marker for infections in relapsed or refractory B-cell all patients treated with CAR T cells","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0032","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0033","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0034","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0036","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0037","unstructured":"Kroger AT, Duchin J, V\u00e1zquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/index.html Accessed November 12, 2018"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0038","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2015-12-550475","article-title":"How I vaccinate blood and marrow transplant recipients","volume":"127","author":"Carpenter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0039","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ymthe.2017.09.008","article-title":"Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products","volume":"26","author":"Cornetta","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/mt.2010.305","article-title":"Solving the problem of gamma-retroviral vectors containing long terminal repeats","volume":"19","author":"Persons","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0041","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0042","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0043","unstructured":"Bryan W. FDA Letter - Biologics License Application. Available at: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM574106.pdf. Accessed 12 November 2018"},{"key":"10.1016\/j.bbmt.2018.12.068_bib0044","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118308905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118308905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:06:06Z","timestamp":1761059166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118308905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1083879118308905"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.068","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}